---
title: "Network Localization of Anxiety in Early Alzheimer's Disease Neurodegeneration"
id: "biorxiv-14-network-localization-of-anxiety-as-an-early-manifestation-of-alzheimer-s"
canonical_url: "https://medichelpline.com/clinical-feed/biorxiv-14-network-localization-of-anxiety-as-an-early-manifestation-of-alzheimer-s"
content_type: "clinical_feed_article"
specialty: "Neurology"
source_name: "bioRxiv (Biomedical Preprints)"
source_url: "https://www.biorxiv.org/content/10.64898/2026.10.24.761536v1?rss=1"
published_at: "2026-10-26T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Network Localization of Anxiety in Early Alzheimer's Disease Neurodegeneration
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/biorxiv-14-network-localization-of-anxiety-as-an-early-manifestation-of-alzheimer-s
- **Specialty:** [Neurology](https://medichelpline.com/clinical-feed/neurology.md)
- **Primary Source:** bioRxiv (Biomedical Preprints)
- **Source URL:** [Original Journal Publication](https://www.biorxiv.org/content/10.64898/2026.10.24.761536v1?rss=1)
- **Published At:** 2026-10-26T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- Investigators examined whether anxiety in cognitively unimpaired older adults aligns with an established **Alzheimer's disease (AD)** atrophy network using MRI and amyloid-beta PET. - The cohort included 1,775 cognitively unimpaired participants with 3T MRI and amyloid PET; anxiety was measured with the STAI-6. - The study team applied Atrophy Network Mapping (ANM), projecting individual cortical atrophy patterns onto a normative functional connectome (N=1000) to derive an anxiety network. - Data indicated greater AD-network atrophy correlated with higher anxiety, independent of depression scores, cognitive performance, cortical atrophy burden, and amyloid load. - The derived **anxiety network** spatially resembled the AD-related atrophy network (reported correlation r=0.74, p=0.04) and a causal anxiety network from lesion/neuromodulation data (r=0.72, p=0.02). - The network convergence generalized across the AD continuum and appeared in an independent Parkinson's disease cohort; investigators tested specificity versus depression and found specificity for anxiety. - Greater atrophy within the anxiety network associated with longitudinal cognitive decline over a mean follow-up of 4.6 years. - The authors concluded anxiety maps onto a brain circuit similar to the AD atrophy network and may serve as an independent marker of early AD-related neurodegeneration. - The report is a preprint and has not been peer reviewed; methods details beyond those presented in the abstract (for example, full ANM parameters and cohort demographics) were not reported in the provided source.
## Clinical Analysis & Structured Key Points
Network Localization of Anxiety as an Early Manifestation of Alzheimer's Disease-related Neurodegeneration | bioRxiv Skip to main content New Results Network Localization of Anxiety as an Early Manifestation of Alzheimer's Disease-related Neurodegeneration Soyoung Lee , Junghee Ha , Arun H. Garimella , Sheena R. Baratono , Grace T. Burt , Helmet T. Karim , Carmen Andreescu , Reisa A. Sperling , Nancy J. Donovan , Michael D. Fox , Shan H. Siddiqi doi: https://doi.org/10.64898/2026.10.24.761536 Soyoung Lee 1 Brigham and Women's Hospital; Find this author on Google Scholar Find this author on PubMed Search for this author on this site For correspondence: soyoung.lee{at}bwh.harvard.edu Junghee Ha 1 Brigham and Women's Hospital; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Arun H. Garimella 1 Brigham and Women's Hospital; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Sheena R. Baratono 1 Brigham and Women's Hospital; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Grace T. Burt 1 Brigham and Women's Hospital; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Helmet T. Karim 2 University of Pittsburgh School of Medicine Find this author on Google Scholar Find this author on PubMed Search for this author on this site Carmen Andreescu 2 University of Pittsburgh School of Medicine Find this author on Google Scholar Find this author on PubMed Search for this author on this site Reisa A. Sperling 1 Brigham and Women's Hospital; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Nancy J. Donovan 1 Brigham and Women's Hospital; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Michael D. Fox 1 Brigham and Women's Hospital; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Shan H. Siddiqi 1 Brigham and Women's Hospital; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Abstract Info/History Metrics Supplementary material Preview PDF Abstract Objective Anxiety is a prominent neuropsychiatric symptom in preclinical Alzheimer's disease (AD), but the neural circuitry linking anxiety and AD remains uncharacterized. We assessed whether anxiety in preclinical AD is independently associated with AD-related neurodegeneration and localizes to a common anxiety network. Methods In cognitively unimpaired (CU) older adults with 3T MRI and amyloid-beta PET (N=1,775), we examined whether an established AD-related atrophy network is associated with anxiety (STAI-6). Then, using Atrophy Network Mapping (ANM), which maps individual cortical atrophy patterns onto a normative functional connectome (N=1000), we derived an anxiety network. We tested its 1) spatial convergence with the AD network and with a causal anxiety network derived from lesion and neuromodulation data, 2) specificity relative to depression, 3) generalizability in samples from independent cohorts with AD and Parkinson's disease (total n=878), and 4) association with longitudinal outcomes. Results In CU older adults, greater AD-network atrophy was associated with higher anxiety, independent of depression, cognition, cortical atrophy, and amyloid burden. Anxiety localized to a network closely resembling the AD network (r=0.74, p=0.04) and the causal anxiety network (r=0.72, p=0.02). This convergence extended across the AD continuum and to the Parkinson's disease cohort and was specific to anxiety relative to depression. Greater anxiety-network atrophy was associated with cognitive decline over 4.6 years. Conclusion Anxiety localizes to a brain circuit resembling the AD-related atrophy network, is consistent across the AD continuum and may extend beyond AD. These findings support anxiety as an independent marker of early AD-related neurodegeneration. Competing Interest Statement SL, JH, AHG, SRB, GTB, HTK, CA, and NJD report no conflicts of interest. RAS has served as a consultant or on scientific advisory boards for AbbVie, AC Immune, Acumen, Aerska, Alector, Altos, Apellis, Biogen, Biohaven, Bristol Myers Squibb, Genentech, GlaxoSmithKline, Ionis Immunobrain, Janssen, Novo Nordisk, Oligomerix, Roche, and Therini over the past 3 years, all under the NIH guidelines of $5k. She also has institutional consulting contracts through the Brigham and Women's Hospital with Eli Lilly and Roche. She has received research funding from Eisai and Eli Lilly for public-private partnership clinical trials. She receives research grant funding from the National Institute on Aging/National Institutes of Health, GHR Foundation, and the Alzheimer's Association. Her spouse, K. Johnson, reports consulting fees from Bristol-Myers Squibb, Janssen, Merck, Novartis, Splink, and Voyager Therapeutics over the past 3 years. MDF has been supported by NIH, the Kaye Family Research Endowment, the Ellison/Baszucki Family Foundation, the Once Upon a Time Foundation, the BD2 Foundation, the Manley Family, the May Family Autism Research Fund, and Chuck and Kerri Bean, and he has received research support from Neuronetics and Boston Scientific; he has served as a consultant for Abbott, Boston Scientific, Magnus Medical, MDC Venture Capital, Soterix, and Tal Medical; he has served on the scientific advisory board of Salma Health; and he has intellectual property on the use of brain connectivity imaging to analyze lesions and guide brain stimulation. SHS has received investigator-initiated research funding from BrainsWay and Neuronetics; he has served as a consultant for Magnus Medical; he has received speaking fees from BrainsWay and Otsuka (for PsychU.org); he has intellectual property involving the use of brain connectivity to target TMS; and he is a shareholder in BrainsWay (publicly traded) and Magnus Medical (not publicly traded). Funder Information Declared NIMH , 2T32MH016259-34 BrainsWay Neuronetics Copyright The copyright holder has placed this preprint in the Public Domain. It is no longer restricted by copyright. Anyone can legally share, reuse, remix, or adapt this material for any purpose without crediting the original authors. Back to top Previous Next Posted October 26, 2026. Download PDF Supplementary Material Email Thank you for your interest in spreading the word about bioRxiv. NOTE: Your email address is requested solely to identify you as the sender of this article. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas. You are going to email the following Network Localization of Anxiety as an Early Manifestation of Alzheimer's Disease-related Neurodegeneration Message Subject (Your Name) has forwarded a page to you from bioRxiv Message Body (Your Name) thought you would like to see this page from the bioRxiv website. Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Share Network Localization of Anxiety as an Early Manifestation of Alzheimer's Disease-related Neurodegeneration Soyoung Lee , Junghee Ha , Arun H. Garimella , Sheena R. Baratono , Grace T. Burt , Helmet T. Karim , Carmen Andreescu , Reisa A. Sperling , Nancy J. Donovan , Michael D. Fox , Shan H. Siddiqi bioRxiv 2026.10.24.761536; doi: https://doi.org/10.64898/2026.10.24.761536 Share This Article: Copy Citation Tools Network Localization of Anxiety as an Early Manifestation of Alzheimer's Disease-related Neurodegeneration Soyoung Lee , Junghee Ha , Arun H. Garimella , Sheena R. Baratono , Grace T. Burt , Helmet T. Karim , Carmen Andreescu , Reisa A. Sperling , Nancy J. Donovan , Michael D. Fox , Shan H. Siddiqi bioRxiv 2026.10.24.761536; doi: https://doi.org/10.64898/2026.10.24.761536 Citation Manager Formats BibTeX Bookends EasyBib EndNote (tagged) EndNote 8 (xml) Medlars Mendeley Papers RefWorks Tagged Ref Manager RIS Zotero Tweet Widget Facebook Like Google Plus One Subject Areas All Articles Animal Behavior and Cognition (8164) Biochemistry (19027) Bioengineering (15171) Bioinformatics (45387) Biophysics (22958) Cancer Biology (20121) Cell Biology (27315) Clinical Trials (138) Developmental Biology (14150) Ecology (21402) Epidemiology (2067) Evolutionary Biology (25818) Genetics (16353) Genomics (23853) Immunology (19037) Microbiology (43213) Molecular Biology (18347) Neuroscience (95164) Paleontology (714) Pathology (3037) Pharmacology and Toxicology (5204) Physiology (8289) Plant Biology (16274) Scientific Communication and Education (2116) Synthetic Biology (4647) Systems Biology (10391) Zoology (2427)
## Related Clinical Research

- [Autism and Menopause: Study Links Autism to More Severe Menopausal Symptoms](https://medichelpline.com/clinical-feed/medical-news-today-0-autism-is-linked-to-more-severe-menopause-symptoms-why.md)
- [ADHD medications lisdexamfetamine and atomoxetine show promise for perimenopausal brain fog](https://medichelpline.com/clinical-feed/medical-news-today-1-2-adhd-medications-show-early-promise-for-perimenopause-focus.md)
- [PACAP Drives Cell-Type–Specific Signaling in the Temporal Association Cortex](https://medichelpline.com/clinical-feed/biorxiv-13-pacap-engages-distinct-signaling-programs-across-cortical-neuronal-and-non.md)
- [Genetic Ancestry Versus Self-Reported Race Alters Neuropsychiatric Symptom Estimates in Alzheimer'](https://medichelpline.com/clinical-feed/medrxiv-21-discordance-between-genetic-ancestry-and-self-reported-race-impacts-inference.md)
- [Psychological flexibility and daily work–caregiving spillover in employed dementia caregivers: DAI](https://medichelpline.com/clinical-feed/plos-one-17-psychological-flexibility-in-the-work-caregiving-interplay-of-employed-family.md)

## Navigation
- [← Back to Neurology Feed](https://medichelpline.com/clinical-feed/neurology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.